학술대회 안내 사전등록 안내 초록등록 안내 초록등록/관리 숙박및교통 안내


мȸ ǥ ʷ


Warning: getimagesize(/home/virtual/circulationadmin/htdocs/econgress/conference/abstract/img_files/finalresultofstudy.jpg) [function.getimagesize]: failed to open stream: No such file or directory in /home/virtual/circulationadmin/new/econgress/conference/manage/schedule/view_abstract.php on line 164
ǥ : ȣ - 500740   258 
Three Years Clinical Outcome of Drug-Eluting Stent implantation for Treatment of In-Stent Restenosis : Korean Multicenter Angioplasty Team (COMATE) Registry
한림대 강남성심병원¹ , 이화여대 목동병원² , 을지대 을지종합병원³ , 연세의대 세브란스병원⁴ ,영동 세브란스병원5 ,원주기독병원6 , 인제대 상계백병원7 , 국민보함공단 일산병원8
최성훈¹, 정재헌¹ , 이상학¹ , 이남호¹ , 권기환² , 유승기³ , 장양수⁴ ,권혁문5 , 윤정한6, 김병옥7 , 양주영8
Background: The objective of this study was to verify of 3 years long term clinical outcome for the treatment of drug eluting stent (DES) implantation in patients with ISR. Methods: In a multi-center cohort of consecutive patients treated with DES between February 2003 and August 2004, 55 patients (age 61.9 ± 8.6 years, male 80.0%) receiving DESs for the treatment of ISR were enrolled. They were treated with 1 or 2 DESs. Clinical outcomes at 1, 6, 12, 24, 36 months were investigated. The primary end point was the incidence of major adverse cardiac events (MACE). Results: 38(69.1%) SESs and 17(30.9%) PESs were implanted. One patient was excluded due to follow-up loss. In remaining 54 patients, three-year clinical outcomes are as follows: At 1 month clinical follow-up, the MACE rate was 1.9% (1 patient; 1 MI & TLR, PES), 6 month, 12.9% (7 patients; 1 MI, 2 TLR, SES; 2 TLR, 2 Death, PES), 12 month, 5.5% (3 patients; 1 TLR, SES; 2 TLR, PES), 24 months, 3.7% (2 patients; 1 TLR, SES; 1 death, PES), 36 months, 0%, respectively. Overall MACE free 3-years survival rate was 75.9%. Overall 3-years MACE free survival rate between SES and PES is statistically higher in SES group (p=0.035). This MACE free survival graphs was below. Conclusion: Drug-eluting stent implantation has the clinical benefit for the long standing safe and effective treatment modality in the treatment of ISR
̹ 󼼺


[ư]